1 week Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,000 shares of the company’s stock, valued at approximately $202,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDXG. Disciplined Growth Investors Inc. MN boosted its stake in MiMedx Group by 0.
8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock worth $2,100,000 after buying an additional 2,737 shares in the last quarter.
IMG Wealth Management Inc. bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $28,000. SkyView Investment Advisors LLC boosted its stake in shares of MiMedx Group by 30.
0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after purchasing an additional 3,000 shares in the last quarter. Principal Financial Group Inc.
grew its holdings in shares of MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc.
now owns 55,495 shares of the company’s stock valued at $328,000 after purchasing an additional 3,292 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in MiMedx Group by 0.7% in the 4th quarter.
Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after purchasing an additional 3,300 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
MiMedx Group Trading Up 0.4 %NASDAQ:MDXG opened at $7.09 on Tuesday.
The firm has a market capitalization of $1.04 billion, a P/E ratio of 12.89 and a beta of 1.
74. MiMedx Group, Inc. has a 52 week low of $5.
47 and a 52 week high of $10.14. The company has a quick ratio of 3.
53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.
The company has a fifty day moving average of $8.08 and a 200 day moving average of $7.98.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.
07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.
21%. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.
42 million. On average, research analysts predict that MiMedx Group, Inc. will post 0.
3 earnings per share for the current year. Wall Street Analyst Weigh InA number of research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.
00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Friday.
View Our Latest Research Report on MiMedx GroupInsiders Place Their BetsIn other news, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.
34. Following the sale, the insider now owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04.
The trade was a 1.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Also, CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.
80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20.
This represents a 14.13 % decrease in their position. The disclosure for this sale can be found here.
In the last 90 days, insiders sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is currently owned by company insiders.
MiMedx Group Company Profile (Free Report)MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.Featured ArticlesFive stocks we like better than MiMedx GroupUsing the MarketBeat Stock Split CalculatorOptions Activity Points to More Volatility for Palantir StockHow to Most Effectively Use the MarketBeat Earnings ScreenerNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Do ETFs Pay Dividends? What You Need to KnowMicroStrategy Sees Insider Buy-Sell Action in Q1.
